Research & Development

share on google plus
Text size
view with small font size
view with medium font size
view with large font size

Global Network

Research Network

Drug discovery research in Kyowa Hakko Kirin Co., Ltd. is implemented by a 4-stronghold structure, that is, Tokyo Research Park and Fuji Research Park in Japan and Kyowa Kirin Pharmaceutical Research, Inc. and Singapore Translational Research Laboratory and these institutions work in concert with each other.
Kyowa Kirin Pharmaceutical Research strengthened coordination with La Jolla Institute for Allergy & Immunology, which is an adjacent non-profitable research institute, and The University of California, San Diego and is engaged in upgrading and expanding product pipelines. Meanwhile, in Singapore, pharmaceutical and biotechnology-based industry became accumulated and has an excellent environment for research & development with full potential. Kyowa Hakko Kirin positions Singapore as a stronghold for translational research from bench-to-bedside and sets its sights on productivity enhancement of research and increase in the success probability of clinical development by active collaboration with research institutions and medical institutions in Singapore. As described above, Kyowa Hakko Kirin is attempting to spur on the creation of innovative new drugs by utilizing a global network of research institutes.

New dimension to translational research
Global government-industry-drug discovery collaboration San Diego Proof-of-concept study using clinical specimens Access to front-line scientific research Promotion of open innovation Japan Creation of development candidates utilizing platform technologies such as antibody technology. Singapore Translation from basic studies to clinical trials using image diagnostic technology.

Development Network

Our challenge to global development of novel drugs involves Asia, US and Europe and other regions keeping close communication between Headquarters in Tokyo, Kyowa Kirin Pharmaceutical Development, Inc. based in the US and UK, Kyowa Hakko Kirin Korea Co., Ltd. in Korea, Kyowa Hakko Kirin China Pharmaceutical Co., Ltd. (China). Of these, Kyowa Kirin Pharmaceutical Development Inc. consisting of offices in the US and in England leads drug development serving as a unified organization across the two regions, named “One Drug Development Organization” (ODDO) to launch the novel drugs in the US and EU which are initially approved in Japan.
For global development products, we have introduced such project structure that promotes knowledge and experiences sharing across the development bases in Asia, US and EU. We plan and execute efficient and compliant drug developments to deliver innovative novel medicines to patients all over the world in a prompt manner.

One Drug Development Organization Europe United States Asia

To Page Top